Case Report: Persistent severe thrombocytopenia after adjuvant ado-trastuzumab emtansine with sequential bone marrow findings and romiplostim support
Frontiers in Oncology · 17.06.2026 · 16
DOI: 10.3389/fonc.2026.1859304 ↗Kurz gefasst
Fallbericht in der Zeitschrift Frontiers in Oncology, online erschienen am 17.06.2026. Verfasst von Dan Qiao und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Shaanxi Provincial Cancer Hospital, Xi'an, Shaanxi, China. Die Arbeit nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Ado-trastuzumab emtansine (T-DM1) remains an established adjuvant option for patients with human epidermal growth factor receptor 2 (HER2)-positive early breast cancer and residual invasive disease after neoadjuvant treatment. Severe, persistent thrombocytopenia deviating from the usual cyclic pattern is uncommon and clinically challenging. We report a 50-year-old woman who developed sustained grade 4 thrombocytopenia after three cycles of adjuvant T-DM1, following prior platinum-based chemotherapy and during adjuvant radiotherapy. The thrombocytopenia was refractory to recombinant human thrombopoietin and hetrombopag. Additional evaluations found no evidence of splenomegaly, peripheral platelet destruction, clonal hematologic disease, or a localized radiation effect on the sampled marrow. Sequential marrow evaluations supported megakaryocytic maturation impairment, with initial depletion followed by quantitative recovery but persistently few platelet-producing forms, without dysplasia or fibrosis. Platelet counts repeatedly declined after romiplostim interruption and recovered after reintroduction, allowing long-term stabilization with a threshold-based intermittent regimen. Following multidisciplinary discussion, further anti-HER2 therapy was withheld because of the severely compromised thrombopoietic reserve. As adjuvant antibody-drug conjugate (ADC) strategies continue to evolve, this case suggests that severe non-cyclic thrombocytopenia may occur early during HER2-directed ADC therapy. It supports the value of sequential marrow assessment in selected refractory cases and provides clinical context for individualized romiplostim support in prolonged thrombocytopenia.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Medical Oncology, Shaanxi Provincial Cancer Hospital, Xi'an, Shaanxi, China.
Zitieren
APA
Qiao, D., Nie, L., Liu, S., & Ding, H. B. (2026). Case Report: Persistent severe thrombocytopenia after adjuvant ado-trastuzumab emtansine with sequential bone marrow findings and romiplostim support. Frontiers in Oncology, 16. https://doi.org/10.3389/fonc.2026.1859304
Vancouver
Qiao D, Nie L, Liu S, Ding HB. Case Report: Persistent severe thrombocytopenia after adjuvant ado-trastuzumab emtansine with sequential bone marrow findings and romiplostim support. Frontiers in Oncology. 2026;16. doi:10.3389/fonc.2026.1859304
BibTeX
@article{Qiao2026,
author = {Qiao, Dan and Nie, Lei and Liu, Shuang and Ding, Hai-Bin},
title = {Case Report: Persistent severe thrombocytopenia after adjuvant ado-trastuzumab emtansine with sequential bone marrow findings and romiplostim support},
journal = {Frontiers in Oncology},
year = {2026},
volume = {16},
doi = {10.3389/fonc.2026.1859304}
}
EUVIMED